A Deschildre1,2, C F Elegbédé3,4, J Just2,5, O Bruyère6, X Van der Brempt2,7, A Papadopoulos3, E Beaudouin2,8, J-M Renaudin2,8, A Crepet3, D-A Moneret-Vautrin2,8,9. 1. CHU Lille, Pediatric Pulmonology and Allergy Department, hôpital Jeanne de Flandre, Lille, France. 2. Allergy Vigilance Network, Vandoeuvre les Nancy, France. 3. Risk Assessment Department (DER), French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Maisons-Alfort, France. 4. French National Institute for Agricultural Research (INRA), Paris Institute of Technology for Life, Food and Environmental Sciences (AgroParisTech), UMR Economie Publique INRA-AgroParisTech, Paris, France. 5. Allergology Department, Centre de l'Asthme et des Allergies, Hôpital d'Enfants Armand-Trousseau, APHP; Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France. 6. Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman, Liège, Belgium. 7. Allergopôle, Clinique Saint-Luc, Bouge (Namur), Belgium. 8. Allergy Department, Centre Hospitalier E Durkheïm, Epinal, France. 9. Lorraine University, Nancy, France.
Abstract
BACKGROUND: The MIRABEL survey is an observational study on peanut allergy in France, Belgium and Luxemburg. The objectives are to provide data on a large population, to analyse the consumer behaviour, to study the presence of peanut traces in pre-packed foods with/without precautionary allergen labelling (PAL), and to combine these data to quantify allergic risk and produce a cost/benefit analysis. This paper reports a real-life observatory of 785 patients (< 16y: 86%): medical characteristics, eliciting doses (ED) in real life and in oral food challenges (OFC), factors associated with severe reactions, allergist dietary advice and patients' anxiety regarding their allergy. METHODS: Age and symptoms at diagnosis, route of exposure, comorbidities, allergy tests, ED (OFC/real life; mg peanut protein), dietary advice about PAL, and anxiety score were recorded. RESULTS: Median age was 3 years; 85% were declared allergic. Severe/potentially severe reactions were reported in 30% of the allergic patients: serious systemic reaction (15%), laryngeal angioedema (8%), shock (4%) and acute asthma (3%); 66% had atopic dermatitis, 58% asthma. Median ara h 2 sIgE level was 11.5 kUA/L. Of the 278 OFCs, 225 were positive (median ED: 67.3 mg). Real-life ED was < 100 mg in 44.3%. Severe reactions were significantly more frequent in teenagers and adults (P = 0.004), asthmatic patients (P = 0.033), and patients who reacted to inhalation (P < 0.001). No significant association was found for OFC ED or ara h 2 sIgE. Factors associated with strict avoidance advice including PAL were OFC ED < 100 mg (P < 0.001), but not severe reaction history (P = 0.051) or asthma (P = 0.34). Anxiety was significantly associated with strict avoidance (P < 0.001). CONCLUSION AND CLINICAL RELEVANCE: Severe/potentially severe reactions, allergic comorbidities, and low EDs in real life are frequent in peanut-allergic patients. Asthma, teenage/adulthood and reaction to inhalation are associated with severe symptoms. PAL and criteria guiding dietary advice need to be improved.
BACKGROUND: The MIRABEL survey is an observational study on peanutallergy in France, Belgium and Luxemburg. The objectives are to provide data on a large population, to analyse the consumer behaviour, to study the presence of peanut traces in pre-packed foods with/without precautionary allergen labelling (PAL), and to combine these data to quantify allergic risk and produce a cost/benefit analysis. This paper reports a real-life observatory of 785 patients (< 16y: 86%): medical characteristics, eliciting doses (ED) in real life and in oral food challenges (OFC), factors associated with severe reactions, allergist dietary advice and patients' anxiety regarding their allergy. METHODS: Age and symptoms at diagnosis, route of exposure, comorbidities, allergy tests, ED (OFC/real life; mg peanut protein), dietary advice about PAL, and anxiety score were recorded. RESULTS: Median age was 3 years; 85% were declared allergic. Severe/potentially severe reactions were reported in 30% of the allergic patients: serious systemic reaction (15%), laryngeal angioedema (8%), shock (4%) and acute asthma (3%); 66% had atopic dermatitis, 58% asthma. Median ara h 2 sIgE level was 11.5 kUA/L. Of the 278 OFCs, 225 were positive (median ED: 67.3 mg). Real-life ED was < 100 mg in 44.3%. Severe reactions were significantly more frequent in teenagers and adults (P = 0.004), asthmatic patients (P = 0.033), and patients who reacted to inhalation (P < 0.001). No significant association was found for OFC ED or ara h 2 sIgE. Factors associated with strict avoidance advice including PAL were OFC ED < 100 mg (P < 0.001), but not severe reaction history (P = 0.051) or asthma (P = 0.34). Anxiety was significantly associated with strict avoidance (P < 0.001). CONCLUSION AND CLINICAL RELEVANCE: Severe/potentially severe reactions, allergic comorbidities, and low EDs in real life are frequent in peanut-allergicpatients. Asthma, teenage/adulthood and reaction to inhalation are associated with severe symptoms. PAL and criteria guiding dietary advice need to be improved.
Authors: Veronique Bajzik; Hannah A DeBerg; Nahir Garabatos; Blake J Rust; Kimberly K Obrien; Quynh-Anh Nguyen; Colin O'Rourke; Alex Smith; Alex H Walker; Charlie Quinn; Vivian H Gersuk; Mary Farrington; David Jeong; Brian P Vickery; Daniel C Adelman; Erik Wambre Journal: Allergy Date: 2022-03-14 Impact factor: 14.710
Authors: Mareen R Datema; Sarah A Lyons; Montserrat Fernández-Rivas; Barbara Ballmer-Weber; André C Knulst; Riccardo Asero; Laura Barreales; Simona Belohlavkova; Frédéric de Blay; Michael Clausen; Ruta Dubakiene; Cristina Fernández-Perez; Philipp Fritsche; David Gislason; Karin Hoffmann-Sommergruber; Monika Jedrzejczak-Czechowicz; Laurian Jongejan; Marek L Kowalski; Tanya Z Kralimarkova; Jonas Lidholm; Nikolaos G Papadopoulos; Todor A Popov; Nayade Del Prado; Ashok Purohit; Isabel Reig; Suranjith L Seneviratne; Athanassios Sinaniotis; Emilia Vassilopoulou; Serge A Versteeg; Stefan Vieths; Paco M J Welsing; E N Clare Mills; Thuy-My Le; Aeilko H Zwinderman; Ronald van Ree Journal: Front Allergy Date: 2021-06-07
Authors: Paul J Turner; Stefania Arasi; Barbara Ballmer-Weber; Alessia Baseggio Conrado; Antoine Deschildre; Jennifer Gerdts; Susanne Halken; Antonella Muraro; Nandinee Patel; Ronald Van Ree; Debra de Silva; Margitta Worm; Torsten Zuberbier; Graham Roberts Journal: Allergy Date: 2022-04-28 Impact factor: 14.710
Authors: Philippe Bégin; John Andrew Bird; Jonathan M Spergel; Dianne E Campbell; Todd D Green; Katharine J Bee; Romain Lambert; Hugh A Sampson; David M Fleischer Journal: Allergy Date: 2021-09-28 Impact factor: 14.710
Authors: Lars Lange; Ludger Klimek; Kirsten Beyer; Katharina Blümchen; Natalija Novak; Eckard Hamelmann; Andrea Bauer; Hans Merk; Uta Rabe; Kirsten Jung; Wolfgang Schlenter; Johannes Ring; Adam Chaker; Wolfgang Wehrmann; Sven Becker; Norbert Mülleneisen; Katja Nemat; Wolfgang Czech; Holger Wrede; Randolf Brehler; Thomas Fuchs; Thilo Jakob; Tobias Ankermann; Sebastian M Schmidt; Michael Gerstlauer; Torsten Zuberbier; Thomas Spindler; Christian Vogelberg Journal: Allergo J Int Date: 2021-09-28